Skip to content
OpenCapital
Get started

Amphastar Pharmaceuticals AMPH Finished Pharmaceutical Products — Revenue

Similar metrics at other companies

HWK
HWKNPharmaceutical — Revenue
$8.32M+15.1%
Kiniksa Pharmaceuticals International, plc logo
KNSAPharmaceutical — Revenue
$214.27M+55.5%
Bausch Health Companies logo
BHCProduct sales — Revenue
$2.5B+12.3%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Product revenues, net
$2.99B+7.8%
Pfizer logo
PFEProduct — Revenue
$11.72B+3.7%
Bristol-Myers Squibb logo
BMYNet product sales — Total Revenues
$11.17B+2.6%

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%
EPS (diluted)$0.14-72.5%

Balance sheet

See full
Cash & equivalents$170.9M-6.5%
Total debt$686.6M+5.2%
Total equity$445.5M—
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%
Free cash flow$38.3M+57.2%

Valuation

See full
Market cap$926.83M-19.9%
Enterprise value$1.44B-11.4%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%—
Debt / equity0.2×—
Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's finished pharmaceutical products — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's finished pharmaceutical products — revenue?
Amphastar Pharmaceuticals (AMPH) reported finished pharmaceutical products — revenue of $171.17M in Q1 2026.
How has Amphastar Pharmaceuticals's finished pharmaceutical products — revenue changed year-over-year?
Amphastar Pharmaceuticals's finished pharmaceutical products — revenue increased by 0.4% year-over-year, from $170.53M to $171.17M.
What is the long-term trend for Amphastar Pharmaceuticals's finished pharmaceutical products — revenue?
Over 2 years (2021 to 2023), Amphastar Pharmaceuticals's finished pharmaceutical products — revenue has grown at a 22.6% compound annual growth rate (CAGR), from $419.57M to $630.27M.
What does finished pharmaceutical products — revenue mean?
This metric represents the total net sales generated from the sale of finished injectable, inhalation, and intranasal pharmaceutical products within the specified business segment. It serves as a primary indicator of market demand and the commercial success of the company's core product portfolio in hospital and clinical settings.